Sean N Parker Foundation

The Sean N. Parker Foundation is one of the most selective philanthropies in American life sciences and civic innovation — and intentionally so. Founded in June 2015 with a $600 million endowment from Sean and Alexandra Parker, the foundation embodies what Parker has called "hack philanthropy": importing Silicon Valley's ethos of bold experimentation, systems-level disruption, and backing visionary founders into the nonprofit world. The foundation does not accept, review, or respond to unsolicited grant applications of any kind. All funding decisions originate internally.

The foundation's grantmaking philosophy begins with problem selection, not organization selection. Staff identify areas where large-scale breakthroughs are possible — cancer immunotherapy, allergy and autoimmunity, malaria elimination, civic technology — and then actively recruit the best leaders to drive those solutions. If no existing organization fits, the foundation may create one (as it did with the Parker Institute for Cancer Immunotherapy in 2016). This means potential grantees must first become visible as field leaders before any relationship with the foundation can develop.

The foundation evaluates potential partners through four explicit lenses: (1) usability — can the solution be adopted by practitioners in the field; (2) impact — will it significantly move the needle on the core problem; (3) sufficiency — are all the necessary conditions in place; and (4) organizational model and leadership quality. Leadership is treated as a differentiating criterion: the foundation explicitly seeks "the right people at a key moment."

Historical commitments illustrate the scale they deploy when alignment is found: $250 million to establish the Parker Institute for Cancer Immunotherapy, $24 million to create the Sean N. Parker Center for Allergy Research at Stanford, $10 million to UCSF's autoimmune lab, and $4.5 million to the UCSF Global Health Group's malaria elimination work. These are multi-year, institutionally anchored relationships — not one-time grants. First-time applicants should understand that entry into this portfolio typically takes years of field-building before foundation attention arrives.

Financial analysis of IRS 990-PF filings reveals a foundation in two distinct phases. During the endowment-deployment era (FY2013–2015), the foundation disbursed between $11M and $64.3M annually, with FY2015 peaking at $64.3M in grants paid as Parker made his foundational institutional commitments. A secondary peak occurred in FY2019 ($19.9M in grants paid), reflecting major civic engagement investments. By FY2021–2023, annual grants paid stabilized at $1.77M–$2.1M, indicating the foundation has transitioned to a steady-state mode maintaining existing partnerships rather than deploying new capital at scale.

From the available DB sample of 10 grants totaling $16.4 million, the average grant is $1.64 million. However, the median is significantly lower, as distribution is dominated by two large commitments: New Venture Fund ($8.62M across 4 grants for community revitalization) and the Obama Foundation ($6.25M, a single grant). This top-two-grantee concentration accounts for 90% of all recorded grant dollars in the sample.

Grant size range is extraordinary: from $500 (Edmundson Art Foundation for a Leonor Fini media clip) to $8.62M (New Venture Fund cumulative). The $37,500 grant to Utah Film Center and $30,000 to Cold Spring Harbor Laboratory represent the foundation's smaller, mission-adjacent commitments. When major programmatic work is excluded, small relationship-maintenance grants of $30K–$100K appear, suggesting a two-tier system: flagship institutional partnerships (multi-million, multi-year) and modest relationship grants to adjacent organizations.

By focus area, the recent DB sample skews heavily toward Civic Engagement (~91% of recorded dollars: New Venture Fund + Obama Foundation + implied Economic Innovation Group support). Life Sciences and Health account for approximately 9% ($1M + $500K for COVID-related work). Arts represent less than 1% of the sample despite being a stated focus area. This likely reflects that the biomedical commitments (PICI, Stanford, UCSF, Weill Cornell) are structured as operating partnerships rather than discrete pass-through grants and thus appear differently in 990 filings.

The foundation's $248.8 million in assets places it in a tier of mid-sized private foundations with substantial capital but highly selective grantmaking. The peers identified by asset proximity are primarily Philanthropy & Grantmaking intermediaries, while the Parker Foundation is better understood as a hybrid operator-funder. The comparison below includes asset-comparable peers alongside select thematic peers for context.

The most striking characteristic of the Parker Foundation relative to peers is its extremely low annual giving-to-assets ratio: approximately 0.85% in FY2023, well below the 5% minimum distribution requirement that most private foundations manage at. This likely reflects the distinction between direct programmatic spending (operating the PICI, allergy center, etc.) and traditional grant disbursements — the foundation's true philanthropic "spend" is substantially higher when operating costs are included. Unlike the asset-comparable peer set — which are primarily grantmakers to external organizations — the Parker Foundation functions in part as an operating foundation that builds and sustains its own institutions.

The most consequential recent development is the February 2024 FDA approval of omalizumab (Xolair) as the first drug approved to reduce allergic reactions to multiple foods after accidental exposure. This milestone is a direct product of the Sean N. Parker Center for Allergy Research at Stanford, which the foundation funded with $24 million beginning in 2014. The approval was widely covered by Stanford Medicine, NPR, and Time magazine in February 2024, representing the foundation's most visible translational science success to date and validating the foundation's decade-long bet on Dr. Kari Nadeau's research program.

In October 2025, the Nobel Prize in Physiology or Medicine was awarded for immune system research — a field the Parker Institute for Cancer Immunotherapy has invested hundreds of millions of dollars to advance. The foundation highlighted this recognition on its news page as affirmation of the immunotherapy paradigm.

In June 2025, CNBC profiled the CEO of the Parker Institute for Cancer Immunotherapy, signaling continued institutional prominence and active leadership. The institute has expanded its network of funded cancer centers since a December 2022 STAT News report on broadened commitments.

The foundation's most recent IRS 990-PF filing was submitted November 14, 2025 (covering FY2023 activity). No new major programmatic announcements were publicly identified for 2025–2026 beyond the Nobel coverage. Michael Polansky continues as Executive Director; Alexandra Lenas Parker, Rakesh Mehta, and Tom Van Loben Sels serve as board members alongside Sean Parker as President.

Because the Sean N. Parker Foundation accepts no unsolicited applications, traditional grant-writing strategies are irrelevant. The actionable path to funding runs entirely through reputation, relationships, and field visibility.

Build standing in Parker-aligned fields first. The foundation monitors four areas: cancer immunotherapy, allergy and autoimmunity, global public health (malaria elimination), and civic technology. Publish in journals that PICI scientists read (Nature, Cell, NEJM, Science Translational Medicine). Present at conferences where Parker Foundation scientific advisors speak. Be cited by researchers already in the Parker network.

Leverage existing grantee institutions as connectors. Stanford, UCSF, Weill Cornell, Penn Medicine, Stand Up to Cancer, the Cancer Research Institute, Code.org, the Economic Innovation Group, and the Obama Foundation are all in the Parker portfolio. A formal affiliation, adjunct appointment, or collaborative project with one of these institutions creates proximity to foundation decision-makers that no cold outreach can replicate.

Establish leadership credentials explicitly. The foundation's stated emphasis on "the right people at a key moment" means personal reputation matters as much as organizational track record. Named professorships, endowed chairs, prestigious awards (MacArthur, Howard Hughes, Nobel), or high-profile advisory roles signal the caliber of leadership the foundation is looking for.

Use the contact channels strategically, not speculatively. General inquiries go to info@parker.org; cancer-related work should contact info@parkerici.org. These should be used only when you have a specific, compelling reason — a transformative new finding, a critical juncture in a program, a direct personal connection — not as a first-introduction cold call.

Think in systems, not programs. The foundation funds interventions that can reshape entire fields. Proposals (informal or otherwise) should articulate how the work could change the standard of care, eliminate a disease class, or restructure civic participation — not how it will serve a specific population over a grant period.

For civic engagement work, consider the fiscal sponsor route. The New Venture Fund has received $8.62 million from the Parker Foundation. If your civic innovation project could be structured under a fiscal sponsor umbrella, this may create a path through an already-trusted intermediary.